Androgen deprivation therapy has no effect on Pim-1 expression in a mouse model of prostate cancer

Jiang Wang1,2, Gang Li1, Bo Li1

  • 1Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China.

Oncology Letters
|June 11, 2017
PubMed

Insights

This study reveals that androgen deprivation therapy (ADT) does not alter Pim-1 gene or protein levels in prostate cancer mouse models. Pim-1 may play a crucial role in prostate cancer progression during ADT.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Prostate cancer progression is often linked to androgen receptor (AR) signaling.
  • Androgen deprivation therapy (ADT) is a standard treatment, but resistance mechanisms are not fully understood.
  • Pim-1, a proto-oncogene serine/threonine kinase, is implicated in cancer cell proliferation and survival.

Purpose of the Study:

  • To investigate the dynamic changes of Pim-1 at the gene and protein levels in mouse models of prostate cancer after surgical castration.
  • To compare Pim-1 expression in androgen-dependent prostate cancer (ADPC), ADT-treated, and androgen-independent prostate cancer (AIPC) groups.
  • To explore the potential role of Pim-1 in prostate cancer during ADT.

Main Methods:

  • Subcutaneous xenograft and orthotopic prostate cancer mouse models were established.
  • Tumor tissues were analyzed using reverse transcription-polymerase chain reaction (RT-PCR), RT-quantitative PCR, ELISA, and immunohistochemistry.
  • Expression levels of Pim-1, prostate-specific antigen (PSA), and AR were quantified.

Main Results:

  • RT-PCR and RT-qPCR showed significant differences in Pim-1 gene expression between ADPC/AIPC and ADT groups.
  • Pim-1 gene amplification products increased in ADT and AIPC groups compared to controls.
  • ELISA indicated varying PSA levels across groups, with significantly lower levels in the ADT group.
  • Immunohistochemistry revealed significant differences in Pim-1 and AR protein expression between ADPC/AIPC and ADT groups.

Conclusions:

  • Androgen deprivation therapy (ADT) did not significantly affect Pim-1 expression at either the gene or protein level in established prostate cancer models.
  • Pim-1 and AR protein levels were significantly altered in androgen-dependent and independent prostate cancer compared to the ADT group.
  • These findings suggest Pim-1 may be important for prostate cancer proliferation and differentiation during ADT, warranting further investigation.